Nadine DuChateau

Are you navigating the complex landscape of sourcing #leukopaks and cellular starting materials for your advanced therapies?     Join us for an on-demand webinar where Matt Chorley, Parijat Jain PhD, and Wini Luty dive into crucial considerations including GMP/GTP compliance and GMP material sourcing efficiency. Gain insights into how to select the right suppliers and streamline your journey through the #CellAndGeneTherapy development pipeline: https://lnkd.in/gZtjSASx     #FDARegulation #CellTherapy #GeneTherapy

15

Cost and speed are critical components in biomanufacturing. See how ÄKTA pilot 600 supports scale-up from process development to GMP clinical scale. Try this ÄKTA system in 3D https://cytiva.link/fajey

3

In conversation with CTMC on Fierce Pharma’s The Top Line Podcast… Our CEO Jason C. Foster joined Jason Bock, CEO and Co-Founder of CTMC, and host Fraiser Kansteiner to explore: 🧫 Challenges and opportunities in developing and commercializing cell therapies 🤝 The value of partnerships between research-based companies and manufacturing organizations 🧬 Why enabling widespread patient access to CGTs requires effort across the industry to scale up production and reduce costs With manufacturers currently unable to meet patient demand and payers and healthcare systems unable to afford widespread patient access, we must challenge the status quo as an industry. By rethinking the development and delivery of these therapies we can meet a threshold beyond just curative efficacy that includes patient access goals. 🎧 Listen now: https://lnkd.in/eZqcG6F4 #CellTherapy #GeneTherapy #Biotechnology #ManufacturingBrighterFutures #PatientAccess CTMC / A joint venture between Resilience + MD Anderson Cancer Center

24

The digitization of 🔬 cell and gene therapies is poised to transform patient care, yet its complexity risks leaving key stakeholders behind. At Autolomous, we recognize the challenges that still exist for those navigating the evolving landscape of these groundbreaking therapies. These barriers can 1️⃣ impede access to crucial data, 2️⃣ hinder collaboration, and 3️⃣ delay the development of life-saving treatments We believe everyone deserves a seat at the table. Stay tuned on May 29th 📢 as we address digital accessibility challenges and fundamentally change the way the CGT industry approaches digital planning 🚀 #innovation #CGT #ComingSoon #autoloMATE #CGTRevolution #ISCT2024

21

1 Comment

The latest U.S. Biotechnology Instruments Market report unveils remarkable growth and new opportunities. Here are 10 essential takeaways for every biotech professional: 1️⃣ Market Growth Projections: The market is set to surge from USD 36.16 billion in 2024 to an impressive USD 49.11 billion by 2033, with a CAGR of 3.46%. 2️⃣ Dominance of Analytical Instruments: Analytical instruments, holding a 65.9% market share in 2023, play a vital role in biotechnological applications, from research to quality control. 3️⃣ Rapid Growth in Cell Culture Instruments: The cell culture instruments segment is poised for the fastest growth through 2033, driven by advancements in biopharmaceuticals, regenerative medicine, and personalized healthcare. 4️⃣ Pharmaceutical & Biotech Companies Lead in End-Use: Dominating the end-use segment with a 40.11% market share in 2023, these companies showcase the industry's dedication to drug discovery and genetic engineering. 5️⃣ Rising Investment in Precision Medicine: With expanding applications, precision medicine presents substantial opportunities, boosting demand for biotechnology instruments crucial for genomic sequencing and biomarker analysis. 6️⃣ Regional Innovation Hubs: California and Massachusetts remain strongholds of biotech innovation, with emerging clusters in Texas and North Carolina contributing significantly to industry growth. 7️⃣ Addressing Regulatory Challenges: Navigating regulatory complexities, especially around gene editing and stem cell research, is crucial for sustaining innovation and market growth. 8️⃣ Global Market Size Estimates: The global biotech instruments market is projected to grow from USD 89.85 billion in 2023 to USD 132.36 billion by 2033, at a CAGR of 3.95%. 9️⃣ Recent Product Innovations: 2024 saw notable advancements, including LICORbio's Odyssey® F biomolecular imaging systems and Waters Corporation’s Alliance iS Bio HPLC System, enhancing productivity and research capabilities. 🔟 Impact of Biopharmaceutical R&D: The expansion of biopharmaceutical R&D, focusing on biologic drugs like monoclonal antibodies and cell therapies, is driving increased demand for sophisticated biotechnology instruments. For those looking to stay ahead, these insights provide a roadmap to understanding market dynamics and seizing growth opportunities. Dive into the full report for an in-depth analysis. Procure Complete Report (220+ Pages PDF with Insights, Charts, Tables, and Figures) @ https://lnkd.in/dGry4wGJ #Biotech #MarketInsights #Innovation #PrecisionMedicine #Genomics #Biopharmaceuticals #BiotechInvestments #RegulatoryAffairs #BiotechResearch #MarketGrowth Let's continue to elevate the biotech industry together! 🚀

2

Demonstrating the technical leadership of SK pharmteco! 🧬 Catch up with our team at ASGCT to discuss how SKPT can support your #cellandgene development!

9

1 Comment

How can you ensure the success of your first #GMP batch? Watch this #webinar to get insights from Jason Modest, industry-leading #CDMO expert, on how to get it Right the First Time. Discover the critical tech transfer approaches that are key to the success of your #API manufacturing program. Learn about critical factors, challenges, and tech transfer methodology to ensure right-first-time readiness and success.

2

Developmental and reproductive toxicology (DART) studies can be difficult to manage. When you need DART support for your chemical product, rely on a partner with more than 90 years of experience. Our environmental Center of Excellence in Greenfield, Indiana, has open capacity to drive quick results. Book your study today. #DARTStudy #OECDStudy #Toxicology

3

The revised Schedule M under the Drugs and Cosmetics Act seeks to uphold quality across the pharmaceutical supply chain, from ingredients to the final drug. In a recent Pharmabiz feature, Dr. Surendra Nath Koduru, Senior Vice President, Regions and Program Operations, US Pharmacopeia, delves into how the revision ensures #Excipient quality. He stresses the policy's aim towards a holistic and risk-based approach to medicine safety and the importance of shared responsibility in the pharmaceutical industry. 👉 Read the article here! https://lnkd.in/gQbvvtwc

13

Demand for peptide-based treatments is on the rise, which is putting more pressure on biopharma QC labs to save resources and increase throughput by modernizing legacy methods. The Alliance iS Bio HPLC System is your ally in making method migration easier and more successful than ever. Read this app note to learn how https://bit.ly/3VGQDIt

13

Thoughts on this? >> Cellular Origins Partners with CGT Catapult on Automated CGT Manufacturing - BioPharm International >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #competitivemarketing #pharma #healthcare

1

Check out this report from Drug Development & Delivery #Pharma #Biotech #CDMO #Formulation #DrugDevelopment #DrugManufacturing

9

#News: Eli Lilly and Company announced Friday that it is investing an additional $5.3 billion in its manufacturing site in #Indiana to boost the capacity for producing #tirzepatide, the active ingredient for the #blockbusterdrugs #Mounjaro and #Zepbound. Lilly said the funds will more than double its investment in a production site in Lebanon, Indiana. The pharma giant was initially going to invest $3.7 billion in April, but Lilly’s latest announcement will now bring the total to $9 billion. The investment aims to enhance the company’s capacity to manufacture the active pharmaceutical ingredient (API) for the wildly popular Mounjaro and Zepbound medications. “Today’s announcement tops the largest manufacturing investment in our company’s history and, we believe, represents the single largest investment in synthetic medicine API manufacturing in U.S. history,” said Lilly CEO David Ricks in a statement. “This multi-site campus will make our latest medicines, including Zepbound and Mounjaro, support pipeline growth and leverage the latest technology and automation for maximum efficiency, safety and quality control.” The Lebanon site plans to add around 200 jobs, mainly in engineering, operating personnel and lab technicians, bringing the total headcount to an estimated 900. Read more from.BioSpace 👇🏽 https://lnkd.in/eM8KT3kg

27

Nxera Pharma, formerly Sosei Heptares, is set to receive $4.6 million in milestone payments from Centessa Pharmaceuticals. Centessa licensed Nxera Pharma technology to help design its novel orexin receptor 2 (OX2R) agonist, ORX750. https://lnkd.in/eKXySM7D Nxera, which has R & D facilities in Cambridge, says the milestone was achieved with clearance of the ORX750 Investigational New Drug application and progression of ORX750 into a Phase 1 clinical trial. The drug is designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1, with potential applicability to narcolepsy type 2, idiopathic hypersomnia and other sleep-wake disorders with normal orexin levels. In-demand Nxera also reveals that it has expanded a strategic R & D partnership with PrecisionLife in a new therapeutic area. The collaboration will leverage novel insights into causal biology within auto-immune disorders to identify fresh targets for drug discovery. PrecisionLife is a Causal AI precision medicine specialist. This is the latest in a series of collaborative agreements between Nxera and PrecisionLife, which began in 2022. The partnership aims to establish new drug targets and subsequently potential precision targeted therapies for auto-immune disorders, each linked to subgroups of patients by PrecisionLife’s mechanism-based patient stratification biomarkers. Matt Barnes, EVP, President of Nxera Pharma UK and Head of R & D, said: “PrecisionLife’s platform for enabling unique insight into disease biology supports our approach to identify the ‘right’ drug target and patient subgroups to leverage our world-leading discovery and early development capabilities and increase our probability of success to provide more effective treatments for patients.”

53

🚀 Join Sannova Analytical for an upcoming webinar to discover how specialized CRO partnerships can better serve small- to mid-size companies. Emerging biopharma and biotech companies often face unique challenges when outsourcing to large, generalized CROs. Delays in sample analysis and lack of access to the “A team” are common issues. The expert panel will discuss the evolving needs of emerging biopharma and biotech, strategies to avoid common outsourcing pitfalls, and how to build partnerships that enhance R&D and drug development efficiency. Learn how to accelerate timelines, manage budgets effectively, and access invaluable scientific and regulatory expertise. 👉 REGISTER HERE: https://buff.ly/3x2fZXU Anitha Krishnan, Ph.D R. John Stubbs Charles Zogas #DrugDevelopment #PharmaceuticalManufacturing #PharmaceuticalSupplyChain #DrugManufacturing #Biopharmaceutical #ClinicalSupplyChain #AnalyticalTesting #BioanalyticalTesting

13

🚀 Join Sannova Analytical for an upcoming webinar to discover how specialized CRO partnerships can better serve small- to mid-size companies. Emerging biopharma and biotech companies often face unique challenges when outsourcing to large, generalized CROs. Delays in sample analysis and lack of access to the “A team” are common issues. The expert panel will discuss the evolving needs of emerging biopharma and biotech, strategies to avoid common outsourcing pitfalls, and how to build partnerships that enhance R&D and drug development efficiency. Learn how to accelerate timelines, manage budgets effectively, and access invaluable scientific and regulatory expertise. 👉 REGISTER HERE: https://buff.ly/3x2fZXU Expert speakers: Anitha Krishnan, Ph.D R. John Stubbs Charles Zogas #DrugDevelopment #PharmaceuticalManufacturing #PharmaceuticalSupplyChain #DrugManufacturing #Biopharmaceutical #ClinicalSupplyChain #AnalyticalTesting #BioanalyticalTesting

3